Literature DB >> 29684997

Protective effect of erythropoietin against lipopolysaccharide induced inflammation and mitochondrial damage in liver.

G X Zhang1, Y J Du2, X H Li3, Z T Feng4, H Zhao1, Y Sun1, J J Jin4, X J Li1.   

Abstract

Recent studies have shown that liver dysfunction is an early event in sepsis. Pre-existing liver dysfunction is a risk factor for progression of infection to sepsis. However, the mechanism of the liver immune response in promoting sepsis and the importance of liver function are not completely understood. In the present study, we investigated the protective effect of erythropoietin (EPO) against mitochondrial dysfunction in a lipopolysaccharide (LPS)-induced sepsis model, and examined the underlying signaling mechanisms. Enzyme linked immunosorbent assay (ELISA) and reactive oxygen species (ROS) analysis were used to evaluate the levels of interleukin (IL)-1β and ROS. The effects of EPO on hepatic mitochondrial function were studied by detecting the mitochondrial DNA (mtDNA) copy number using real-time PCR (RT-PCR). To explore the mechanism of action of EPO in sepsis, protein expressions of IL-1β, caspase-1 and NLRP3 were assessed by Western blotting; liver histopathology and ultrastructure of liver mitochondria was examined by transmission electron microscopy. We found that LPS treatment increased serum IL-1β and ROS levels, the effect of which was attenuated by EPO. Moreover, LPS treatment also increased the mtDNA copy number and the protein expressions of IL-11β, caspase-1, and NLRP3, which were suppressed by EPO. Histological examination of liver showed LPS-induced cellular edema in hepatic lobules, lymphocytic infiltration and hepatocellular necrosis; these changes were also alleviated by EPO treatment. On electron microscopy, the size of hepatocellular mitochondria in the LPS group was smaller than that in the control group, and the changes were reversed by EPO in the LPS+EPO group. Our results suggest that EPO alleviated liver and mitochondrial damage induced by LPS, possibly via inhibition of NLRP3 signaling.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29684997

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  3 in total

Review 1.  Pyroptosis in Liver Disease: New Insights into Disease Mechanisms.

Authors:  Jiali Wu; Su Lin; Bo Wan; Bharat Velani; Yueyong Zhu
Journal:  Aging Dis       Date:  2019-10-01       Impact factor: 6.745

2.  Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?

Authors:  Azar Hadadi; Masoud Mortezazadeh; Kasra Kolahdouzan; Golbarg Alavian
Journal:  J Med Virol       Date:  2020-04-19       Impact factor: 2.327

Review 3.  Immune-mediated approaches against COVID-19.

Authors:  Helena F Florindo; Ron Kleiner; Daniella Vaskovich-Koubi; Rita C Acúrcio; Barbara Carreira; Eilam Yeini; Galia Tiram; Yulia Liubomirski; Ronit Satchi-Fainaro
Journal:  Nat Nanotechnol       Date:  2020-07-13       Impact factor: 40.523

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.